Edinburgh Medical Technology Acceleration to Exit EMTATE

Lead Research Organisation: University of Edinburgh

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding.  It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.

Publications

10 25 50
 
Description CRUK (TEMo-SIGN)
Amount £2,000,000 (GBP)
Funding ID C17950/A26783 
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 07/2018 
End 06/2023
 
Description Dutch Lung Foundation - IL-33 in Asthma CiC4
Amount € 20,000,000 (EUR)
Organisation Long Fonds 
Sector Charity/Non Profit
Country Netherlands
Start 01/2018 
End 12/2019
 
Description EPSRC - One size anti embolism stockings CIC4
Amount £33,729 (GBP)
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Academic/University
Country United Kingdom
Start  
 
Description EuroImmun (CINck project CIC4)
Amount £96,144 (GBP)
Organisation Euroimmun 
Start 09/2018 
End 06/2019
 
Description Hypertension study (Vampire CIC4)
Amount £100,000 (GBP)
Organisation Optos plc 
Start  
 
Description Innovation Initiative Grant - Anti embolism stocking
Amount £750 (GBP)
Organisation British Council 
Department Global Innovation Initiative grant
Sector Charity/Non Profit
Country United Kingdom
Start 12/2017 
End 12/2017
 
Description Institutional Translational Partnership Award iTPA (Corticosterone therapy)
Amount £19,440 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2018 
End 02/2019
 
Description MRC CASE studentship (Vampire CIC4)
Amount £70,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start  
 
Description MRC Proximity to Discovery (CINck CIC4)
Amount £1,500 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 07/2018 
End 07/2018
 
Description MRC Proximity to Discovery (Vampire CIC4)
Amount £9,850 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 08/2018 
End 10/2018
 
Description New Investigator research grant: IL-33 severe allergic asthma
Amount £553,566 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 08/2018 
End 07/2021
 
Description Optos - Vampire App CiC4
Amount £216,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start  
 
Description RSE - efinger CiC4
Amount £47,000 (GBP)
Organisation Royal Society of Edinburgh (RSE) 
Sector Learned Society
Country United Kingdom
Start  
 
Description Scottish Enterprise High Growth - efinger CiC4
Amount £10,000 (GBP)
Organisation Scottish Enterprise 
Sector Public
Country United Kingdom
Start 09/2017 
End 12/2017
 
Description TU/JBCT (efinger CIC4)
Amount £86,000 (GBP)
Organisation Urology Foundation 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description The Urology Foundation - efinger CiC4
Amount £58,000 (GBP)
Organisation Urology Foundation 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description Travel award (CINck CIC4)
Amount £2,000 (GBP)
Organisation Microbiology Society 
Sector Learned Society
Country Unknown
Start 02/2017 
End 02/2017
 
Description iCURE - Anti embolism stocking CiC4
Amount £35,000 (GBP)
Organisation Innovation to Commercialisation of University Research 
Sector Charity/Non Profit
Country Unknown
Start 01/2018 
End 03/2018
 
Title Developed assays (Vaccines CIC4) 
Description As part of this project we have developed and established a suite of assays that can be applied to studies of vaccine/adjuvant candidates in cattle. This includes refined standard operating procedures that can be shared with other research teams. We have stored a biobank of material at The Roslin Institute that will enable us, in the future, to determine further the underlying mechanisms by which Cobalt nanoparticles provide adjuvant activity. This is a valuable resource which makes best use of animals funded through the CiC project taking into account the 3Rs principles. 
Type Of Material Technology assay or reagent 
Year Produced 2018 
Provided To Others? Yes  
Impact No impact to date. 
 
Title Multiplex array-based assay (Rheumatoid Arthritis CIC4) 
Description This study has resulted in the development of a multiplex array-based assay that allows for the detection of autoantibodies against a large number of specific peptide sequences in rheumatoid arthritis (RA) patient sera, using a relatively small amount of material. This assay can be adapted in order to test autoreactivity against further protein sequences containing the post-translational modification citrullination, or other protein modifications. 
Type Of Material Technology assay or reagent 
Year Produced 2018 
Provided To Others? No  
Impact No impact until IP protection has been completed and further funding secured. 
 
Title Precise dectection of breast and endometrial cancer (TEMo-SIGN CIC4) 
Description We developed a signature using machine learning that allows the detection of breast and endometrial cancer with a precision that is superior of current diagnostic techniques. Our method has the potential to be miniaturized to a chip level in order to be easily and rapidly used at clinical level; moreover we created a unique RNA-SEQ dataset of patients in cancer. 
Type Of Material Improvements to research infrastructure 
Year Produced 2016 
Provided To Others? No  
Impact No impact to date - looking at creating a spin out company and are in advanced discussions with a VC company. 
 
Title Web App (Vampire CIC4) 
Description The wider VAMPIRE project is a collaboration between the Universities of Edinburgh and Dundee and the Web App has been adopted as our primary means of analysing fundus camera images. VAMPIRE provides a platform from which to facilitate new studies/users including potential income generation to sustain and develop the Web App system as well for developing new technologies (i.e. new additional software for analysing images) and applying for our own grant funding. 
Type Of Material Data analysis technique 
Year Produced 2017 
Provided To Others? Yes  
Impact The Web App represents a crucial development for our group that will have significant impact on current and prospective activities. 
 
Description Alan Boyd Consultants (Corticosterone project CIC4) 
Organisation Boyds
PI Contribution Formal agreement in place to work with Alan Boyd Consultants on Wellcome Trust iTPA
Collaborator Contribution Formal agreement in place to work with Alan Boyd Consultants on Wellcome Trust iTPA
Impact Award commenced Oct 2018 so no outcomes to report at this stage.
Start Year 2018
 
Description Benchmark Animal Health - novel adjuvant for improved vaccine delivery CIC4 
Organisation Benchmark Animal Health
PI Contribution CiC helped expand this ongoing partnership.
Collaborator Contribution Using data generated through the CiC project we have provided advice to them on suitable adjuvant/antigen combinations and concentrations enabling them to initiate further in-house studies. These will allow further translation studies assessing the novel adjuvant in aquaculture alongside our studies in ruminants, and previously in mice. none, the novel adjuvant already had a patent submitted prior to this study. As part of our ongoing collaboration with Benchmark Animal Health we are involved with patent applications in additional territories (Benchmark are providing funds to support these applications).
Impact no outputs to date
Start Year 2017
 
Description CiC 2014 (cryopreserved hESC) 
Organisation Cardiff University
Country United Kingdom 
Sector Academic/University 
PI Contribution New collaboration with Dr Mariah Lelos (Cardiff University). In December, 2015 we transported cryopreserved midbrain dopaminergic (mDA) precursors to Dr Lelos' lab for transplantation into immune-compromised rats.
Collaborator Contribution transplantation into immune-compromised rats
Impact This is a direct application of the know-how gained from this MRC CiC project.
Start Year 2015
 
Description CiC2014 (tablet for AD diagnosis) 
Organisation NHS Scotland
Country United Kingdom 
Sector Public 
PI Contribution Tablet AD for detection
Collaborator Contribution To further increase the rate of recruitment of patients with mild Alzheimer's disease
Impact To further increase the rate of recruitment of patients with mild Alzheimer's disease we have then widened our recruitment area beyond Stirling to include two consultants at the Community Hospital in Falkirk: Drs Debbie Browne and Parvez Thekkumpurath have agreed to refer patients with mild Alzheimer's disease to our study. The study has also been added to the Join Dementia Research (JDR) register, which is a national register of over 14,000 patients and healthy individuals interested in taking part in dementia research. This service allows prospective participants, who meet eligibility criteria for a study, to express interest in taking part and provides researchers with the contact details of interested patients. This will increase the rate of recruitment for both the current study and future work.
Start Year 2015
 
Description DROIA - Early diagnosis of breast and ovarian cancer CIC4 
Organisation DROIA nv
PI Contribution Intellectual property. Well developed conversations around the potential spin out with this VC company.
Collaborator Contribution Well developed conversations around the potential spin out with this VC company. Aiming for significant investment in 2018.
Impact No outcomes to date but very advanced discussion and multiple meetings.
Start Year 2017
 
Description Edinburgh BioSciences Ltd (Vampire app CIC4) 
Organisation Edinburgh Biosciences Ltd
Country United Kingdom 
Sector Private 
PI Contribution Discovery research
Collaborator Contribution Expertise
Impact No outcomes to date
Start Year 2016
 
Description Endura - One size embolism stocking CiC4 
Organisation Endura Ltd
PI Contribution Medical device opportunity
Collaborator Contribution Endura are interested in exploring new market for the technology in addition to the medical devices opportunity. Collaborator on EPSRC grant which was secured and reported in further funding.
Impact Successfully secured an EPSRC grant and opened the opportunity up to other potential markets
Start Year 2017
 
Description EuroImmun (CINck CIC4) 
Organisation Euroimmun
PI Contribution The aim of this project is to perform a head to head comparison of L1 based HPV DNA target amplification tests with those that are E6/E7 based for the detection of HPV in high-grade and invasive disease within different biological matrices
Collaborator Contribution The primary outcome will be to assess hrHPV prevalence between the assays in the different sample types. Secondary outcome will look at type specific concordance information is available. A tertiary outcome of the project will be to look at degradation of samples and its effect on hrHPV positivity over time. For this we will use fresh LBC samples and perform testing using the four assays at multiple time points after storage.
Impact Project ongoing, no outcomes to report to date
Start Year 2018
 
Description Heriot Watt University (efinger CIC4) 
Organisation Heriot-Watt University
Country United Kingdom 
Sector Academic/University 
PI Contribution Work on Super Resolution Imaging (Ultrasound) in the diagnosis of prostate cancer in collaboration with Assoc. Professors Vassilis Sboros and Weiping Lu.
Collaborator Contribution Work undertaken by Assoc Professors as noted above.
Impact The collaboration has resulted in a successful application to the CSO Scotland that will fund a 2 year project evaluating the use of SRI in the diagnosis of prostate cancer (TCS/18/40)
Start Year 2016
 
Description MedImmune - Suppression of IL-33 in severe allergic asthma CIC4 
Organisation MedImmune Ltd
Country United Kingdom 
Sector Private 
PI Contribution Project idea / IP
Collaborator Contribution Collaboration allowed project to test HpARI in human IL-33 transgenic mice, and also giving extremely valuable technical advice on the biophysics of IL-33 binding.
Impact no outcomes to date
Start Year 2016
 
Description Optos - Vampire app CiC4 
Organisation Optos plc
Department Optos
Country United Kingdom 
Sector Private 
PI Contribution Provided intellectual property
Collaborator Contribution Optos provided funding for 2 x PhDs totalling £216000. Reporting in further funding.
Impact 2 x PhD and further funding in progress from company.
Start Year 2017
 
Description Quay Pharma (Corticosterone CIC4) 
Organisation Quay Pharma
PI Contribution Discovery research
Collaborator Contribution Expertise
Impact No outcomes to report to date
Start Year 2016
 
Description Therakind (Corticosterone CiC4) 
Organisation TheraKIND
Country United Kingdom 
Sector Private 
PI Contribution Academic discovery research
Collaborator Contribution Consultation has been obtained with Therakind (a paediatric formulation/marketing specialist) who have expressed interest and offered support in kind and the prospect of funding and down-stream collaboration once a drug product is available.
Impact No outcomes to report yet
Start Year 2016
 
Description Wide Blue - eFinger CIC4 
Organisation Wideblue Limited
PI Contribution IP and vision
Collaborator Contribution collaborated on submission to Innovate UK. and will work with the project (spin out) to develop the device to the stage of small batch manufacture.
Impact no outputs to report
Start Year 2017
 
Description cic 2014 (cryopreserved hESC) 
Organisation Asymptote
Country United Kingdom 
Sector Private 
PI Contribution stem cells
Collaborator Contribution Asymptote controlled-rate freezers for cryopreserving cells for clinical application
Impact new improved methods
Start Year 2015
 
Title ASSAY 
Description The present invention relates to methods of determining the clinical significance of an HPV infection in a subject and associated methods, systems and kits. The method involves detection of biomarkers associated with clinically significant HPV infections and associated dysplasia. 
IP Reference WO2016193682 
Protection Patent application published
Year Protection Granted 2016
Licensed No
Impact A UK priority submission has been filed by the University of Edinburgh (27th May 2015) to cover the use of the chemokines (at both protein and mRNA levels) for the determination of clinically significant HPV infection, with associated methods, systems and kits. The named inventors are the applicants of this grant, and have access through the University. The patent was published in December 2016 (WO2016/193682) and filed in Europe (EP3304081) and US (US2018163279) in 2018
 
Title IMMUNOMODULATORY AGENT 
Description The present invention relates to a polypeptide comprising HpARI domain 2 and: -a. a DNA-binding domain, and/or b. HpARI domain 3, the polypeptide having an inhibitory effect on IL-33 activity. The invention relates further to a related nucleic acid, expression vector, host cell, pharmaceutical composition use in method of treatment, for example for use in treating allergic or inflammatory disorders. The invention also relates to a method of treating allergic or inflammatory disorder, and a ex vivo method of inhibiting IL-33, wherein these methods involve the use of the polypeptide. 
IP Reference WO2019030542 
Protection Patent application published
Year Protection Granted 2019
Licensed No
Impact Spin out discussions are underway with experienced entrepreneurs.
 
Title METHODS FOR CANCER DIAGNOSIS USING A GENE EXPRESSION SIGNATURE 
Description The present invention relates to the field of cancer diagnosis and treatment. The present invention provides methods of diagnosing cancer, prognosing cancer, predicting efficacy of treatment for cancer, assessing outcome of treatment for cancer or assessing recurrence of cancer comprising the steps of a) analysing a biological sample obtained from a subject to determine the presence of target molecules representative of expression of at least four biomarkers selected from the group consisting of MCTP1, PIBF1, TMTC2, ANKRD32, CEPT1, ZNF114, CRYBG3, IFI16, PPIF, SCD, RP11-469M7.1, PTP4A1 and NRIP1; and b) comparing the expression levels of the biomarkers determined in (a) with one or more reference values, wherein a difference in the expression of the biomarkers in the sample from the subject compared to the one or more reference values is indicative of cancer presence or absence. The invention further provides methods of treating cancer, and devices and kits for use in the methods of the invention. 
IP Reference WO2018150179 
Protection Patent application published
Year Protection Granted 2018
Licensed No
Impact A spin out is under construction and in discussion with 4 x Venture Capital companies, advanced discussions with one VC company.
 
Title New AES (CIC4) 
Description A new AES has been developed, which has the ability to cover a very large portion of the population and deliver almost the correct pressures. Feedback from a clinical evaluation of nine stockings has shown that eight out of nine patients found them easier to don and doff, and found the new AES more comfortable. The pressures exerted by the new AES demonstrate compression gradients, which are closer to international standards. 
Type Of Technology New/Improved Technique/Technology 
Year Produced 2018 
Impact A pressure sensor company already in existence more than 16 years, are eager to combine technology once we have established our product and/or brand in the market place Therefore, a huge amount of potential to take this project forward to the wider market place. Potential to license the technology and currently exploring this option. 
 
Title New spectroscopic method 
Description We have developed new spectroscopic methods for measuring the health of pre-transplant livers. As a result of our collaboration with DSTL and Metrohm we will have access to a new spectrometer (not yet commercially available) that could enable better measurements of spectra in the operating theatre. 
Type Of Technology New/Improved Technique/Technology 
Year Produced 2018 
Impact Will report on impact once method becomes commercially available 
 
Title Retinal image analysis improvement (Vampire CIC4) 
Description Imaging the retina could become a quick test for identifying disease in the human body and brain. To unlock this potential researchers from around the world investigate associations between the retina and conditions such as hypertension, kidney disease, diabetes, cardiovascular disease and dementia. However, this requires access to specialist software that will measures retinal images in an accurate and reliable way. We possess this expertise and the software through our successful VAMPIRE project. We propose delivering these computerised measurements through a web-based App, enabling our software to be utilised by many more researchers than we are currently able to reach. By charging for access we will sustain and grow the facility, especially as empowering present research will very likely see future activity involving drug development (with the retina as a source of outcome measures to assess efficacy) and large-scale population screening programmes to identify at-risk individuals for more effective interventions. 
Type Of Technology New/Improved Technique/Technology 
Year Produced 2017 
Impact As a result of the project, significant improvements have been made to the analysis of retinal images, including: 1. Enhanced human-computer interface, which is more efficient and gives a better user experience. 2. Robust handling of images from different devices with different resolutions 3. Superior measurement processes with more reliable outputs 4. Scalability - i.e. can handle more users and more images than ever before 5. Easier to maintain and update than previous means of delivering software 
 
Title Rheumatoid Arthritis CIC4 
Description We have developed a new multiplex array based assay for the profiling of autoantibodies against citrullinated peptide sequences in human serum. We have adapted the Reverse Phase Protein Microarray (RPPA) platform to immobilise the modified peptides, as well as unmodified controls, on glass slides, using previously existing technologies. The slides are incubated with a small amount (40 microlitters) of human serum so that antibodies against those sequences are retained on the slide via antibody-antigen interactions. We have optimised a protocol for the detection of those autoantibodies using biotin labelled anti-human IgG secondary antibodies and a streptavidin-conjugated fluorophore, which can then be read using the Innopsys IR 710 scanner. The data is then processed using Mapix software and analysed bioinformatically. All bioinformatic tools used were previously available and adapted for the purposes of these datasets. However, further work may lead to the development of new types of software that are best suited for this analysis, for example in incorporating clinical information such as disease onset, symptoms etc. This assay allows us to test a large number of peptide sequences and controls (currently up to 360 unique sequences) using a small amount of serum. For comparison, about 18 sequences had been tested previously and the current assays use only a small subset of those. Our assay can therefore significantly accelerate progress in both disease diagnosis and basic research. Although similar multiplex platforms have been developed previously, the knowledge of citrullinated peptide sequences to test was lacking. Therefore, this is the first multiplex assay of its kind. 
Type Of Technology New Material/Compound 
Year Produced 2018 
Impact No impact to date, IP protection to be discussed further. 
 
Company Name Precidar Diagnostics 
Description Precise diagnostics for improved cervical screening. Precidar Diagnostics has been successfully accepted as a High Growth Ventures company by Scottish Enterprise (SE) and as part of this we ae getting support from a dedicated commercial advisor who is an expert in the field of diagnostic assay development- Dr Paula Wittels. We are supported by two commercial advisors - Dr Murdo Black and Dr Sandy Primrose who are both well reputed in the diagnostic field in the UK. We are in discussion with investors both VC and angel funds. We have had recent discussion with 8 roads in China. We are in discussion with potential commercial partners - Euroimmun and Luminex We are also in discussion with other national and international organisations to work collaboratively on this project. Some of them are - University of Strathclyde, London School of Hygiene and Tropical medicine, Newcastle Diagnostics Operative Co-operation, Coombe Women's Hospital and University of Dublin, Ireland; Suzhou institute of biomedical engineering and technology, Institute of Epidemiology, Brussels. 
Year Established 2015 
Impact This company failed to get investment and closed in October 2018.
 
Description Easter Bush Science Outreach Centre (Vaccines CIC4) 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Schools
Results and Impact Information on the potential for novel adjuvants such as the Cobalt nanoparticles studied in the CiC project was included in educational material provided as part of scientific resource for the new Easter Bush Science Outreach Centre. The information may be included in educational activities for secondary school pupils aiming to understand disease control/diagnostics and the value of research in driving improved strategies.
Year(s) Of Engagement Activity 2018
 
Description Edinburgh Fringe Show - CINck 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Cervical Cancer - You're history
Edinburgh Fringe Show at part of the Cabaret of Dangerous Idea
Year(s) Of Engagement Activity 2017
 
Description Patient advice obtained (Corticosterone CIC4) 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Patients, carers and/or patient groups
Results and Impact Patient advice has been obtained from the Addison's Disease Self-Help Group and Congenital Adrenal Hyperplasia patient support group.
Year(s) Of Engagement Activity 2017
 
Description Presentation at Scottish Colposcopy meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Presented 'HPV molecular testing and biomarkers for improved cervical disease management' on 11th November
Year(s) Of Engagement Activity 2016
 
Description Scottish HPV Investigators Network 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact New markers of cervical infection, immunity and disease
Year(s) Of Engagement Activity 2016
 
Description Sunday Times article (efinger CIC4) 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact An article was included in a supplement to the Sunday Times in 2016 highlighting the work of this project
Year(s) Of Engagement Activity 2016
 
Description Talks to IET by Bob Reuben (efinger CIC4) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Addressed talks to the Institute of Engineering Technology which sparked a q&a session following the talk
Year(s) Of Engagement Activity 2016
 
Description Talks to RSSA by Bob Reuben (efinger CIC4) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Policymakers/politicians
Results and Impact Addressed talks to the Royal Scottish Society of Arts following by a q&a session.
Year(s) Of Engagement Activity 2016
 
Description Veterinary symposium (Vaccines CIC4) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Poster presentation at International Veterinary Immunology Symposium 2017
Year(s) Of Engagement Activity 2017